Lantern Pharma posts investor presentation on AI-driven oncology drug development platform and pipeline

Lantern Pharma, Inc.

Lantern Pharma, Inc.

LTRN

0.00
  • Lantern Pharma highlighted its AI platform RADR, citing 88% accuracy for patient stratification to support targeted oncology trials.
  • Management framed RADR as a lever to cut early-stage development timelines by 70% and costs by 80%.
  • LP-300 NSCLC program remains in Phase 2; interim data cited an 86% clinical benefit rate and 87% disease control rate as of May 11, 2026.
  • Trial focus shifted to EGFR exon 21 L858R; median PFS cited at 8.4 months with target lesion decreases in over 70% of evaluable patients.
  • LP-184 completed Phase 1a enrollment; LP-284 is in Phase 1; PredictBBB cited 94% benchmark accuracy for blood-brain barrier permeability prediction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.